A client who is receiving magnesium sulfate has a urine output of 20 mL/hr. Which of the following medications should the nurse expect to administer?

Choice A reason: This is incorrect because extravasation is not related to the lifetime cumulative dose limit of doxorubicin, but to the leakage of the medication from the vein into the surrounding tissue. Extravasation can cause severe tissue damage and necrosis, and should be prevented by using a central venous catheter and monitoring the infusion site.

Choice B reason: This is incorrect because red tinged urine and sweat are not related to the lifetime cumulative dose limit of doxorubicin, but to the normal excretion of the medication from the body. Red tinged urine and sweat are expected side effects of doxorubicin and do not indicate toxicity or harm.

Choice C reason: This is correct because an excess amount of doxorubicin can lead to cardiomyopathy, which is a serious and potentially fatal complication of the medication. Cardiomyopathy is a condition in which the heart muscle becomes weak and unable to pump blood effectively. The risk of cardiomyopathy increases with the cumulative lifetime dose of doxorubicin, which should not exceed 450 to 550 mg/m2.

Choice D reason: This is incorrect because myelosuppression is not related to the lifetime cumulative dose limit of doxorubicin, but to the dose-dependent effect of the medication on the bone marrow. Myelosuppression is a condition in which the production of blood cells is reduced, leading to anemia, leukopenia, and thrombocytopenia. Myelosuppression can be managed by adjusting the dose and frequency of doxorubicin and monitoring the blood counts.

Choice A reason: Suppressing respiratory effort is the correct purpose of pancuronium. Pancuronium is a neuromuscular blocking agent that paralyzes the skeletal muscles, including the respiratory muscles. This prevents the client from breathing spontaneously and allows the mechanical ventilator to control the ventilation. Pancuronium is used to improve oxygenation and prevent barotrauma in clients with ARDS, who have severe hypoxemia and stiff lungs.

Choice B reason: Decreasing chest wall compliance is not the correct purpose of pancuronium. Chest wall compliance is the measure of how easily the chest wall expands during inspiration. Decreasing chest wall compliance means increasing the resistance to lung expansion, which can worsen the ventilation and oxygenation in clients with ARDS. Pancuronium does not affect the chest wall compliance, but rather the muscle tone.

Choice C reason: Decreasing respiratory secretions is not the correct purpose of pancuronium. Respiratory secretions are the mucus and fluid that are produced by the respiratory tract to moisten and protect the airways. Decreasing respiratory secretions can cause dryness and irritation of the mucous membranes, which can increase the risk of infection and inflammation. Pancuronium does not affect the respiratory secretions, but rather the nerve impulses.

Choice D reason: Inducing sedation is not the correct purpose of pancuronium. Sedation is a state of reduced consciousness, awareness, or responsiveness. Inducing sedation can help to reduce anxiety, pain, and agitation in clients who are mechanically ventilated. Pancuronium does not induce sedation, but rather paralysis. Pancuronium does not affect the central nervous system, but rather the peripheral nervous system. The nurse should administer a sedative agent, such as propofol or midazolam, along with pancuronium to ensure the client's comfort and safety.